trending Market Intelligence /marketintelligence/en/news-insights/trending/xbebzk6sk8dwprvcl-pxcq2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Regulus terminates chief medical officer as part of restructuring

Blog

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Video

Climate Credit Analytics: Linking climate scenarios to financial impacts

Blog

Global M&A Infographic Q1 2021

Blog

Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge


Regulus terminates chief medical officer as part of restructuring

Regulus Therapeutics Inc. said Mark Deeg will be terminated as its chief medical officer as part of the restructuring process to preserve capital.

The San Diego-based biopharmaceutical company has paused its recruitment activities for RG-012, its potential treatment for Alport syndrome, and a phase 1 trial of RGLS4326, another kidney disease drug.

Regulus is reducing its workforce by about 60% and expects to complete the reduction in the third quarter. It expects the restructuring to yield over $20 million in annualized savings, extending its cash runway into mid-2019.